Skip to main content

EHS Training

EHS has completed the new on line Introduction to Laboratory Safety Course, this course replaces the monthly classroom offerings and removes any remaining barriers to full compliance by anyone working in a DC laboratory specifically undergraduates with class conflicts.

 

Introduction to Laboratory Safety on line course

 

Radiation Safety Classroom Training - Contact EHS 646-1762

Subcommittee for Clinical Gene Transfer

Institutional Biosafety Committee - Subcommittee for Clinical Gene Transfer (IBC-SCGT)

The Dartmouth College Institutional Biosafety Committee - Subcommittee for Clinical Gene Transfer (IBC-SCGT) is a multidisciplinary committee charged with the review of clinical protocols involving gene transfer as defined in the NIH Guidelines For Research Involving Recombinant Or Synthetic Nucleic Acid Molecules, March 2013. This will include, (1) review of the scientific principles and objectives of the clinical gene transfer protocol; (2) review of the protocol for concerns of the safety of personnel, the community, and the environment and (3) review to determine whether all appropriate requirements as stated in the NIH Guidelines have been fulfilled prior to initiation of the protocol. The sub-committee has the authority to approve, require modifications in, or disapprove all research activities that fall within its jurisdiction. All new clinical gene transfer protocols and amendments to existing protocols are subject to review by the sub-committee. This sub-committee reports to the Dartmouth Institutional Biosafety Committee and the Committee for Protection of Human Subjects (CPHS), the IRB at Dartmouth.

Important Information Every Investigator Must Know About IBC-SCGT Approval

IBC-SCGT ByLaws

Refer to the IBC-SCGT ByLaws to learn more about the subcommittee review and oversight process and the scope of the committee's oversight. 

Standard Operating Procedure (SOP)for Protocol Submission to the IBC-SCGT

Refer the SOP for Protocol Submission as a guide for investigators to compile all required information for IBC-SCGT review.  This can be used as a checklist for protocol documentation and throughout the protocol review process.

Local Standard Operating Procedure (SOP) for the Study Agent

Refer to the Local SOP and complete all required information, then submit this SOP, along with all other protocol documentation, for IBC-SCGT review.  This is a required document by the IBC-SCGT to analyze the risks associated with the potential study hazards. 

NIH Guidelines For Research Involving Recombinant Or Synthetic Nucleic Acid Molecules

Refer to the NIH Guidelines for the regulations regarding protocol submission (Appendix M) to the Recombinant DNA Advisory Committee (RAC), as well as the responsibilities for all primary investigators.

 

Clinical Gene Transfer Subcommittee Members:

Deborah A. Hogan, Ph.D., IBC Chair/Microbiology and Immunology

Lionel Lewis, BCH, MD, IBC-SCGT Chair/Medicine/Pharmacology & Toxicology

Brian J. O'Shea, Ph.D., Biological Safety Officer, Environmental Health & Safety

Maureen O'Leary, Ph.D., MBA, CBSP, Director, Environmental Health and Safety

Elizabeth Bankert, MA, Assistant Provost/Human Subjects Protection Official

Rebecca Rogers, NCCC, Office of Clinical Research

Dianne Ferris, Human Research Analyst, CPHS

Douglas D. Parr, Pharm.D, Investigational Pharmacy

Richard J. Powell, MD, Chief, Section of Vascular Surgery

Brent Berwin, Ph.D., IBC Member, Microbiology/Immunology

 

Last Updated: 9/4/13